Are localized prostate cancer biomarkers useful in the clinical practice?

Prostate cancer presents itself in a heterogeneous way with both aggressive and indolent forms. Despite the controversy surrounding its use, prostate-specific antigen screening ultimately leads to a greater number of diagnosed patients. One of the biggest challenges in clinical practice is to select...

Full description

Saved in:
Bibliographic Details
Published inTumor biology Vol. 40; no. 9; pp. 101042831879925 - 1010428318799255
Main Authors Carneiro, Arie, Priante Kayano, Paulo, Gomes Barbosa, Álan Roger, Langer Wroclawski, Marcelo, Ko Chen, Carolina, Cavlini, Giulio Costa, Reche, Guilherme Jose, Sanchez-Salas, Rafael, Tobias-Machado, Marcos, Sowalsky, Adam G, Bianco, Bianca
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.09.2018
SAGE Publishing
Subjects
Biomarkers, Tumor - metabolism
Humans
Male
Prognosis
Prostate - metabolism
Prostate-Specific Antigen - metabolism
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - metabolism
PCA3
Prostate Health Index
ExoDx
biomarkers
ConfirmMDx
4K score
Oncotype
Prostate cancer
prostate-specific antigen
SelectMDx
Online AccessGet full text
ISSN1010-4283
1423-0380
1423-0380
DOI10.1177/1010428318799255

Cover

Abstract Prostate cancer presents itself in a heterogeneous way with both aggressive and indolent forms. Despite the controversy surrounding its use, prostate-specific antigen screening ultimately leads to a greater number of diagnosed patients. One of the biggest challenges in clinical practice is to select the right patients for biopsy and, among diagnosed patients, to differentiate tumors with an indolent course from those with an unfavorable prognosis, in order to determine the best therapeutic decision for each case, avoiding unnecessary interventions. Currently, several types of biomarkers are available for clinical use in patients with prostate cancer, which include blood-based (prostate-specific antigen, Prostate Health Index®, 4K score®); urine sample-based (PCA3, SelectMDx®, ExoDx Prostate IntelliScore®); and biopsy, transurethral resection, or radical prostatectomy tissue-based (ConfirmMDx®, Oncotype®, Prolaris®, Decipher®). The aim of this review is to provide an overview of the current state of evidence and to highlight recent advances in the evaluation and diagnosis of prostate cancer, with emphasis on biomarkers related to diagnosis and to prognostic evaluation of localized prostate cancer.
AbstractList Prostate cancer presents itself in a heterogeneous way with both aggressive and indolent forms. Despite the controversy surrounding its use, prostate-specific antigen screening ultimately leads to a greater number of diagnosed patients. One of the biggest challenges in clinical practice is to select the right patients for biopsy and, among diagnosed patients, to differentiate tumors with an indolent course from those with an unfavorable prognosis, in order to determine the best therapeutic decision for each case, avoiding unnecessary interventions. Currently, several types of biomarkers are available for clinical use in patients with prostate cancer, which include blood-based (prostate-specific antigen, Prostate Health Index®, 4K score®); urine sample-based (PCA3, SelectMDx®, ExoDx Prostate IntelliScore®); and biopsy, transurethral resection, or radical prostatectomy tissue-based (ConfirmMDx®, Oncotype®, Prolaris®, Decipher®). The aim of this review is to provide an overview of the current state of evidence and to highlight recent advances in the evaluation and diagnosis of prostate cancer, with emphasis on biomarkers related to diagnosis and to prognostic evaluation of localized prostate cancer.Prostate cancer presents itself in a heterogeneous way with both aggressive and indolent forms. Despite the controversy surrounding its use, prostate-specific antigen screening ultimately leads to a greater number of diagnosed patients. One of the biggest challenges in clinical practice is to select the right patients for biopsy and, among diagnosed patients, to differentiate tumors with an indolent course from those with an unfavorable prognosis, in order to determine the best therapeutic decision for each case, avoiding unnecessary interventions. Currently, several types of biomarkers are available for clinical use in patients with prostate cancer, which include blood-based (prostate-specific antigen, Prostate Health Index®, 4K score®); urine sample-based (PCA3, SelectMDx®, ExoDx Prostate IntelliScore®); and biopsy, transurethral resection, or radical prostatectomy tissue-based (ConfirmMDx®, Oncotype®, Prolaris®, Decipher®). The aim of this review is to provide an overview of the current state of evidence and to highlight recent advances in the evaluation and diagnosis of prostate cancer, with emphasis on biomarkers related to diagnosis and to prognostic evaluation of localized prostate cancer.
Prostate cancer presents itself in a heterogeneous way with both aggressive and indolent forms. Despite the controversy surrounding its use, prostate-specific antigen screening ultimately leads to a greater number of diagnosed patients. One of the biggest challenges in clinical practice is to select the right patients for biopsy and, among diagnosed patients, to differentiate tumors with an indolent course from those with an unfavorable prognosis, in order to determine the best therapeutic decision for each case, avoiding unnecessary interventions. Currently, several types of biomarkers are available for clinical use in patients with prostate cancer, which include blood-based (prostate-specific antigen, Prostate Health Index®, 4K score®); urine sample-based (PCA3, SelectMDx®, ExoDx Prostate IntelliScore®); and biopsy, transurethral resection, or radical prostatectomy tissue-based (ConfirmMDx®, Oncotype®, Prolaris®, Decipher®). The aim of this review is to provide an overview of the current state of evidence and to highlight recent advances in the evaluation and diagnosis of prostate cancer, with emphasis on biomarkers related to diagnosis and to prognostic evaluation of localized prostate cancer.
Prostate cancer presents itself in a heterogeneous way with both aggressive and indolent forms. Despite the controversy surrounding its use, prostate-specific antigen screening ultimately leads to a greater number of diagnosed patients. One of the biggest challenges in clinical practice is to select the right patients for biopsy and, among diagnosed patients, to differentiate tumors with an indolent course from those with an unfavorable prognosis, in order to determine the best therapeutic decision for each case, avoiding unnecessary interventions. Currently, several types of biomarkers are available for clinical use in patients with prostate cancer, which include blood-based (prostate-specific antigen, Prostate Health Index®, 4K score®); urine sample-based (PCA3, SelectMDx®, ExoDx Prostate IntelliScore®); and biopsy, transurethral resection, or radical prostatectomy tissue-based (ConfirmMDx®, Oncotype®, Prolaris®, Decipher®). The aim of this review is to provide an overview of the current state of evidence and to highlight recent advances in the evaluation and diagnosis of prostate cancer, with emphasis on biomarkers related to diagnosis and to prognostic evaluation of localized prostate cancer.
Author Carneiro, Arie
Cavlini, Giulio Costa
Tobias-Machado, Marcos
Bianco, Bianca
Gomes Barbosa, Álan Roger
Ko Chen, Carolina
Priante Kayano, Paulo
Langer Wroclawski, Marcelo
Reche, Guilherme Jose
Sanchez-Salas, Rafael
Sowalsky, Adam G
AuthorAffiliation 3 Department of Urology, Institut Mutualiste Montsouris, Paris, France
2 Discipline of Urology, Department of Surgery, Hospital Israelita Albert Einstein, São Paulo, Brazil
1 Discipline of Urology, Department of Surgery, Faculdade de Medicina do ABC, São Paulo, Brazil
5 Center for Human Reproduction and Genetics, Department of Collective Health, Faculdade de Medicina do ABC, São Paulo, Brazil
4 Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
AuthorAffiliation_xml – name: 1 Discipline of Urology, Department of Surgery, Faculdade de Medicina do ABC, São Paulo, Brazil
– name: 3 Department of Urology, Institut Mutualiste Montsouris, Paris, France
– name: 4 Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
– name: 2 Discipline of Urology, Department of Surgery, Hospital Israelita Albert Einstein, São Paulo, Brazil
– name: 5 Center for Human Reproduction and Genetics, Department of Collective Health, Faculdade de Medicina do ABC, São Paulo, Brazil
Author_xml – sequence: 1
  givenname: Arie
  orcidid: 0000-0002-0152-0513
  surname: Carneiro
  fullname: Carneiro, Arie
– sequence: 2
  givenname: Paulo
  surname: Priante Kayano
  fullname: Priante Kayano, Paulo
– sequence: 3
  givenname: Álan Roger
  surname: Gomes Barbosa
  fullname: Gomes Barbosa, Álan Roger
– sequence: 4
  givenname: Marcelo
  surname: Langer Wroclawski
  fullname: Langer Wroclawski, Marcelo
– sequence: 5
  givenname: Carolina
  surname: Ko Chen
  fullname: Ko Chen, Carolina
– sequence: 6
  givenname: Giulio Costa
  orcidid: 0000-0001-7730-8618
  surname: Cavlini
  fullname: Cavlini, Giulio Costa
– sequence: 7
  givenname: Guilherme Jose
  surname: Reche
  fullname: Reche, Guilherme Jose
– sequence: 8
  givenname: Rafael
  surname: Sanchez-Salas
  fullname: Sanchez-Salas, Rafael
– sequence: 9
  givenname: Marcos
  surname: Tobias-Machado
  fullname: Tobias-Machado, Marcos
– sequence: 10
  givenname: Adam G
  surname: Sowalsky
  fullname: Sowalsky, Adam G
– sequence: 11
  givenname: Bianca
  surname: Bianco
  fullname: Bianco, Bianca
  email: bianca.bianco@fmabc.br
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30204063$$D View this record in MEDLINE/PubMed
BookMark eNp9UUlv1DAUtlARXeDOCeXIJeAtcXwBVRXLSJW4wNl6sZ-nHjzxYCdI8OtxmFLRSnCxrfdtT_7OycmUJiTkOaOvGFPqNaOMSj4INiitedc9ImdMctFSMdCT-q5wu-Kn5LyUHaWs07p_Qk4F5VTSXpyRzWXGJiYLMfxE1xxyKjPM2FiYLOZmDGkP-Svm0iwF_RKbMDXzTcVjmEJVVQXYOVh8-5Q89hALPru9L8iX9-8-X31srz992FxdXrdWDqxrhdUOVTcC770F5CPTEtnoFAwd41Zyzz24ESQ6AYgIctDSam_HzmrpnLggm6OvS7Azhxzqgj9MgmB-D1LeGsh1o4jGKuVA-E5z1LIDNVrfcVmjOPaK-6F6vTl6HZZxj87iNGeI90zvI1O4Mdv03fR9_cF-NXh5a5DTtwXLbPahWIwRJkxLMZxRLtZDVeqLv7PuQv50UQn0SLC1hJLR31EYNWvd5mHdVdI_kNhQ6wtp3TbE_wnbo7DAFs0uLXmqnf2b_wuOb7vd
CitedBy_id crossref_primary_10_1007_s11934_024_01219_3
crossref_primary_10_1155_2019_7894017
crossref_primary_10_1177_03008916241261484
crossref_primary_10_26508_lsa_202302146
crossref_primary_10_17650_1726_9776_2019_15_4_18_29
crossref_primary_10_3390_cancers13164162
crossref_primary_10_3390_biomedicines11041051
crossref_primary_10_1590_1414_431x2021e11439
crossref_primary_10_1038_s41391_021_00422_4
crossref_primary_10_23736_S2724_6051_20_04160_0
crossref_primary_10_1007_s11845_021_02723_y
crossref_primary_10_1002_pros_23977
crossref_primary_10_3390_cancers12051268
Cites_doi 10.1056/NEJM198710083171501
10.1200/JCO.2012.42.6858
10.1016/S0022-5347(17)32528-4
10.1016/j.juro.2013.02.005
10.1016/j.biotechadv.2016.11.009
10.1148/radiol.2016152542
10.1200/JCO.2014.59.0026
10.1111/iju.13326
10.1111/j.1464-410X.2010.09286.x
10.1016/S0022-5347(05)65271-8
10.1038/pcan.2016.58
10.1038/pcan.2016.15
10.1016/j.eururo.2014.11.030
10.1016/S0090-4295(02)01958-1
10.1016/j.urology.2016.01.012
10.1186/1471-2164-14-690
10.1016/j.juro.2013.04.119
10.1016/j.ijrobp.2013.04.043
10.1007/s13277-013-0854-4
10.1200/JCO.2012.46.4396
10.1097/01.ju.0000095460.12999.43
10.1002/pros.22898
10.1016/j.juro.2010.12.032
10.1016/j.urolonc.2014.12.002
10.1590/s1679-45082017ed4151
10.1038/sj.bjc.6605815
10.1016/j.urology.2014.02.035
10.1001/jama.1995.03530150038031
10.1186/s12885-015-1623-0
10.1016/j.cca.2014.06.025
10.1016/j.juro.2014.02.003
10.1111/bju.13861
10.1016/j.urology.2015.12.008
10.1016/j.juro.2012.08.219
10.1002/pros.23197
10.1002/pros.23096
10.1200/JCO.2013.52.8505
10.1016/j.eururo.2014.08.010
10.1186/1741-7015-6-19
10.1016/j.eururo.2014.10.021
10.1016/j.juro.2014.10.121
10.1016/S1470-2045(10)70295-3
10.1016/j.eururo.2014.05.004
10.1038/sj.bjc.6605058
10.3310/hta19870
10.1007/s00428-014-1540-7
10.1158/1078-0432.CCR-14-3334
10.1016/j.juro.2007.11.038
10.1016/j.juro.2013.12.005
10.1185/03007995.2014.899208
10.1038/bjc.2012.39
10.1016/j.eururo.2016.08.003
10.1177/2051415816656121
10.1016/j.eururo.2014.05.039
10.1097/PAS.0000000000000530
10.1016/j.juro.2014.04.013
10.4103/1008-682X.125390
10.1016/j.cca.2013.10.022
10.1097/COH.0b013e32833ed177
10.1001/jamaoncol.2016.0097
10.1016/j.prnil.2016.07.002
10.1016/j.urology.2006.12.014
10.6004/jnccn.2016.0004
10.1016/j.eururo.2017.02.026
10.1038/bjc.2015.223
10.1371/journal.pone.0066855
10.1111/bju.13465
10.1016/j.juro.2013.06.017
10.1016/j.eururo.2010.10.024
10.1016/j.ucl.2015.08.001
10.1016/j.juro.2016.04.057
10.1016/j.eururo.2016.04.012
10.1016/j.eururo.2012.07.030
ContentType Journal Article
Copyright The Author(s) 2018
Copyright_xml – notice: The Author(s) 2018
DBID AFRWT
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1177/1010428318799255
DatabaseName SAGE Journals GOLD Open Access 2024
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic



MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: AFRWT
  name: Sage Journals GOLD Open Access 2024
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
EISSN 1423-0380
EndPage 1010428318799255
ExternalDocumentID oai_doaj_org_article_c77da3f592e945a7bcf524d7a2e672f8
PMC6602068
30204063
10_1177_1010428318799255
10.1177_1010428318799255
Genre Journal Article
Review
GrantInformation_xml – fundername: Intramural NIH HHS
  grantid: Z99 CA999999
GroupedDBID ---
.GJ
06D
0R~
0VX
0VY
0~B
123
1N0
203
29Q
29~
2KM
2LR
2VQ
30V
30W
328
36B
4.4
408
40D
53G
67N
7X7
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8UI
8UJ
96X
AAIAL
AAJKR
AARHV
AARTL
AASGM
AAWCG
AAYIC
AAYIU
AAYQN
AAYTO
AAYZH
AAZMS
ABBTS
ABFSG
ABJOX
ABPLI
ABTEG
ABTHY
ABTMW
ABUWG
ABWCG
ACBXY
ACGFS
ACKNC
ACPQW
ACPRK
ACQXL
ACSTC
ADAGL
ADBBV
ADHIR
ADKPE
ADZMO
AEGNC
AEJHL
AENEX
AEOHA
AEPYU
AETCA
AEWDL
AEYAO
AEZWR
AFBBN
AFCOW
AFDXO
AFHIU
AFKRA
AFKRG
AFLOW
AFRWT
AFSIO
AFWTZ
AFZKB
AGAYW
AGJBK
AGQMX
AGWZB
AGYKE
AHAVH
AHBYD
AHMBA
AHSBF
AHWEU
AHYZX
AIIXL
AIXLP
AJBLW
AJUZI
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
ANMIH
AUTPY
AYAKG
AZQEC
BBNVY
BCNDV
BDDNI
BENPR
BGNMA
BHPHI
BPHCQ
BSEHC
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
CYUIP
DU5
DWQXO
E0A
EBD
EBS
EJD
EMB
EMOBN
EN4
ESBYG
F5P
FB.
FRRFC
FYJPI
FYUFA
GGRSB
GNUQQ
GQ7
GROUPED_DOAJ
GUQSH
H13
HCIFZ
HF~
HMCUK
HMJXF
HRMNR
HZ~
IOS
ITM
J0Z
J8X
JBSCW
K.F
KOV
LK8
M1P
M2O
M4Y
M7P
N9A
NQS
NU0
O1H
O9-
O93
O9I
OK1
PADUT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
Q2X
R9I
RIG
ROL
RSV
RXVBD
S1Z
S27
S3A
S3B
SAUOL
SBL
SCNPE
SFC
SHX
SOJ
SV3
T13
U2A
U9L
UDS
UG4
UJ6
UKHRP
VC2
W48
WK8
Z45
ZOVNA
ZXP
~A9
AAYXX
ACHEB
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
7X8
5PM
ID FETCH-LOGICAL-c4815-3c9de75ba26fcae2b194e1bd7a8512c42f2fadba4ed3aeeea4894c9fcb5c94dd3
IEDL.DBID AFRWT
ISSN 1010-4283
1423-0380
IngestDate Wed Aug 27 01:28:47 EDT 2025
Thu Aug 21 17:49:46 EDT 2025
Thu Sep 04 21:14:09 EDT 2025
Mon Jul 21 06:08:06 EDT 2025
Tue Jul 01 02:20:40 EDT 2025
Thu Apr 24 22:55:37 EDT 2025
Tue Jun 17 22:33:00 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords PCA3
Prostate Health Index
ExoDx
biomarkers
ConfirmMDx
4K score
Oncotype
Prostate cancer
prostate-specific antigen
SelectMDx
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4815-3c9de75ba26fcae2b194e1bd7a8512c42f2fadba4ed3aeeea4894c9fcb5c94dd3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0002-0152-0513
0000-0001-7730-8618
OpenAccessLink https://journals.sagepub.com/doi/full/10.1177/1010428318799255?utm_source=summon&utm_medium=discovery-provider
PMID 30204063
PQID 2102321027
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_c77da3f592e945a7bcf524d7a2e672f8
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6602068
proquest_miscellaneous_2102321027
pubmed_primary_30204063
crossref_primary_10_1177_1010428318799255
crossref_citationtrail_10_1177_1010428318799255
sage_journals_10_1177_1010428318799255
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-09-01
PublicationDateYYYYMMDD 2018-09-01
PublicationDate_xml – month: 09
  year: 2018
  text: 2018-09-01
  day: 01
PublicationDecade 2010
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: United States
PublicationTitle Tumor biology
PublicationTitleAlternate Tumour Biol
PublicationYear 2018
Publisher SAGE Publications
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: SAGE Publishing
References Mohler, Armstrong, Bahnson 2016; 14
de Kok, Verhaegh, Roelofs 2002; 62
Ploussard, Haese, Van Poppel 2010; 106
Greene, Elshafei, Nyame 2016; 76
Carter, Albertsen, Barry 2013; 190
Wroclawski 2017; 15
Loeb, Sanda, Broyles 2015; 193
Ross, Den, Yousefi 2016; 19
Klein, Cooperberg, Magi-Galluzzi 2014; 66
Vickers, Cronin, Aus 2008; 6
Brand, Zhang, Crager 2016; 89
Partin, Van Neste, Klein 2014; 192
Stewart, Van Neste, Delvenne 2013; 189
Cooperberg, Davicioni, Crisan 2015; 67
Leyten, Hessels, Smit 2015; 21
Raaijmakers, Kirkels, Roobol 2002; 60
Klein, Haddad, Yousefi 2016; 90
Narayan, Konety, Warlick 2017; 24
Nguyen, Martin, Choeurng 2017; 20
Cuzick, Stone, Fisher 2015; 113
Rubio-Briones, Borque, Esteban 2015; 15
McShane, Hayes 2012; 30
Catalona, Partin, Sanda 2011; 185
Lepor, Catalona, Loeb 2016; 43
Jakobsen, Hamdy, Bryant 2016; 9
Capoluongo, Zambon, Basso 2014; 429
Rosenkrantz, Ginocchio, Cornfeld 2016; 280
Wroclawski, Serpa-Neto, Fonseca 2013; 34
Parekh, Punnen, Sjoberg 2015; 68
Washino, Okochi, Saito 2017; 119
Marks, Fradet, Deras 2007; 69
Moldovan, Van den Broeck, Sylvester 2017; 72
Freedland, Gerber, Reid 2013; 86
Garisto, Klotz 2017; 31
Cooperberg, Simko, Cowan 2013; 31
O’Leary, Wright, Brister 2016; 44
Crawford, Scholz, Kar 2014; 30
Sharma, Zapatero-Rodriguez, O’Kennedy 2017; 35
Jablonka, Alves Ba, de Oliveira 2014; 436
Bishoff, Freedland, Gerber 2014; 192
Mottet, Bellmunt, Bolla 2017; 71
Elshafei, Chevli, Moussa 2015; 75
Catalona, Smith, Wolfert 1995; 274
Epstein, Egevad, Amin 2016; 40
Cuzick, Berney, Fisher 2012; 106
Nilsson, Skog, Nordstrand 2009; 100
Cantiello, Russo, Ferro 2015; 33
McKiernan, Donovan, O’Neill 2016; 2
Nordstrom, Vickers, Assel 2015; 68
Nicholson, Mahon, Boland 2015; 19
Wojno, Costa, Cornell 2014; 7
Bradley, Palomaki, Gutman 2013; 190
Deras, Aubin, Blase 2008; 179
Hansen, Auprich, Ahyai 2013; 63
Gupta, Roobol, Savage 2010; 103
Strimbu, Tavel 2010; 5
Mertan, Greer, Shih 2016; 196
Knezevic, Goddard, Natraj 2013; 14
Catalona, Bartsch, Rittenhouse 2003; 170
Karnes, Bergstralh, Davicioni 2013; 190
Den, Yousefi, Trabulsi 2015; 33
Carter, Walsh, Landis 2002; 167
McGrath, Christidis, Perera 2016; 4
Van der Kwast 2014; 464
Chevli, Duff, Walter 2014; 191
Seisen, Roupret, Brault 2015; 75
Van Neste, Hendriks, Dijkstra 2016; 70
Erho, Crisan, Vergara 2013; 8
Stamey, Yang, Hay 1987; 317
Auprich, Chun, Ward 2011; 59
Luo, Gou, Huang 2014; 16
Wei, Feng, Partin 2014; 32
Cuzick, Swanson, Fisher 2011; 12
Dijkstra, Govers, Hendriks 2017; 120
Cullen, Rosner, Brand 2015; 68
Smith, Catalona 1994; 152
Ankerst, Hoefler, Bock 2014; 83
Partin AW (bibr69-1010428318799255) 2014; 192
Catalona WJ (bibr20-1010428318799255) 2003; 170
Luo Y (bibr66-1010428318799255) 2014; 16
Epstein JI (bibr9-1010428318799255) 2016; 40
Wei JT (bibr52-1010428318799255) 2014; 32
Deras IL (bibr49-1010428318799255) 2008; 179
Thomas Gillispie Smith MC (bibr1-1010428318799255) 2017
Sharma S (bibr3-1010428318799255) 2017; 35
Elshafei A (bibr55-1010428318799255) 2015; 75
Stewart GD (bibr31-1010428318799255) 2013; 189
Karnes RJ (bibr76-1010428318799255) 2013; 190
Ploussard G (bibr25-1010428318799255) 2010; 106
Cuzick J (bibr36-1010428318799255) 2015; 113
Bishoff JT (bibr38-1010428318799255) 2014; 192
Bradley LA (bibr48-1010428318799255) 2013; 190
Catalona WJ (bibr19-1010428318799255) 2011; 185
McKiernan J (bibr30-1010428318799255) 2016; 2
Cuzick J (bibr35-1010428318799255) 2012; 106
Nicholson A (bibr65-1010428318799255) 2015; 19
McShane LM (bibr14-1010428318799255) 2012; 30
Marks LS (bibr24-1010428318799255) 2007; 69
Mottet N (bibr62-1010428318799255) 2017; 71
Jakobsen NA (bibr8-1010428318799255) 2016; 9
Lepor A (bibr59-1010428318799255) 2016; 43
Erho N (bibr39-1010428318799255) 2013; 8
Moldovan PC (bibr42-1010428318799255) 2017; 72
Parekh DJ (bibr21-1010428318799255) 2015; 68
de Kok JB (bibr22-1010428318799255) 2002; 62
Jablonka F (bibr10-1010428318799255) 2014; 436
O’Leary NA (bibr26-1010428318799255) 2016; 44
Cooperberg MR (bibr34-1010428318799255) 2013; 31
Freedland SJ (bibr73-1010428318799255) 2013; 86
Greene DJ (bibr56-1010428318799255) 2016; 76
Gupta A (bibr68-1010428318799255) 2010; 103
Wroclawski ML (bibr11-1010428318799255) 2013; 34
Smith DS (bibr17-1010428318799255) 1994; 152
Strimbu K (bibr12-1010428318799255) 2010; 5
Knezevic D (bibr32-1010428318799255) 2013; 14
Brand TC (bibr72-1010428318799255) 2016; 89
Den RB (bibr77-1010428318799255) 2015; 33
Seisen T (bibr60-1010428318799255) 2015; 75
Van der Kwast TH (bibr7-1010428318799255) 2014; 464
Auprich M (bibr23-1010428318799255) 2011; 59
Rubio-Briones J (bibr54-1010428318799255) 2015; 15
Capoluongo E (bibr67-1010428318799255) 2014; 429
Narayan VM (bibr2-1010428318799255) 2017; 24
Cooperberg MR (bibr40-1010428318799255) 2015; 67
Stamey TA (bibr15-1010428318799255) 1987; 317
Wojno KJ (bibr70-1010428318799255) 2014; 7
Klein EA (bibr33-1010428318799255) 2014; 66
Chevli KK (bibr50-1010428318799255) 2014; 191
Dijkstra S (bibr28-1010428318799255) 2017; 120
Nordstrom T (bibr64-1010428318799255) 2015; 68
Garisto JD (bibr5-1010428318799255) 2017; 31
Raaijmakers R (bibr6-1010428318799255) 2002; 60
Nilsson J (bibr29-1010428318799255) 2009; 100
Cuzick J (bibr37-1010428318799255) 2011; 12
Cullen J (bibr71-1010428318799255) 2015; 68
Mohler JL (bibr46-1010428318799255) 2016; 14
Washino S (bibr45-1010428318799255) 2017; 119
Van Neste L (bibr27-1010428318799255) 2016; 70
Mertan FV (bibr43-1010428318799255) 2016; 196
Wroclawski ML (bibr4-1010428318799255) 2017; 15
Catalona WJ (bibr18-1010428318799255) 1995; 274
Carter HB (bibr47-1010428318799255) 2013; 190
Carter HB (bibr16-1010428318799255) 2002; 167
Leyten GH (bibr57-1010428318799255) 2015; 21
Loeb S (bibr58-1010428318799255) 2015; 193
Crawford ED (bibr74-1010428318799255) 2014; 30
Hansen J (bibr53-1010428318799255) 2013; 63
Klein EA (bibr41-1010428318799255) 2016; 90
Rosenkrantz AB (bibr44-1010428318799255) 2016; 280
Ankerst DP (bibr51-1010428318799255) 2014; 83
Cantiello F (bibr61-1010428318799255) 2015; 33
Vickers AJ (bibr63-1010428318799255) 2008; 6
Nguyen PL (bibr75-1010428318799255) 2017; 20
Ross AE (bibr78-1010428318799255) 2016; 19
McGrath S (bibr13-1010428318799255) 2016; 4
References_xml – volume: 6
  year: 2008
  article-title: A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden
  publication-title: BMC Med
– volume: 75
  start-page: 1951
  issue: 16
  year: 2015
  end-page: 1957
  article-title: PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy
  publication-title: Prostate
– volume: 24
  start-page: 352
  issue: 5
  year: 2017
  end-page: 360
  article-title: Novel biomarkers for prostate cancer: an evidence-based review for use in clinical practice
  publication-title: Int J Urol
– volume: 30
  start-page: 4223
  issue: 34
  year: 2012
  end-page: 4232
  article-title: Publication of tumor marker research results: the necessity for complete and transparent reporting
  publication-title: J Clin Oncol
– volume: 12
  start-page: 245
  issue: 3
  year: 2011
  end-page: 255
  article-title: Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study
  publication-title: Lancet Oncol
– volume: 67
  start-page: 326
  issue: 2
  year: 2015
  end-page: 333
  article-title: Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort
  publication-title: Eur Urol
– volume: 40
  start-page: 244
  issue: 2
  year: 2016
  end-page: 252
  article-title: The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system
  publication-title: Am J Surg Pathol
– volume: 83
  start-page: 1362
  issue: 6
  year: 2014
  end-page: 1368
  article-title: Prostate Cancer Prevention Trial Risk Calculator 2.0 for the prediction of low- versus high-grade prostate cancer
  publication-title: Urology
– volume: 21
  start-page: 3061
  issue: 13
  year: 2015
  end-page: 3070
  article-title: Identification of a candidate gene panel for the early diagnosis of prostate cancer
  publication-title: Clin Cancer Res
– volume: 190
  start-page: 389
  issue: 2
  year: 2013
  end-page: 398
  article-title: Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer
  publication-title: J Urol
– volume: 63
  start-page: 201
  issue: 2
  year: 2013
  end-page: 209
  article-title: Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay
  publication-title: Eur Urol
– volume: 76
  start-page: 1019
  issue: 11
  year: 2016
  end-page: 1023
  article-title: External validation of a PCA-3-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy
  publication-title: Prostate
– volume: 90
  start-page: 148
  year: 2016
  end-page: 152
  article-title: Decipher genomic classifier measured on prostate biopsy predicts metastasis risk
  publication-title: Urology
– volume: 14
  start-page: 19
  issue: 1
  year: 2016
  end-page: 30
  article-title: Prostate cancer, Version 1.2016
  publication-title: J Natl Compr Canc Netw
– volume: 33
  start-page: 944
  issue: 8
  year: 2015
  end-page: 951
  article-title: Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy
  publication-title: J Clin Oncol
– volume: 71
  start-page: 618
  issue: 4
  year: 2017
  end-page: 629
  article-title: EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent
  publication-title: Eur Urol
– volume: 31
  issue: 5
  year: 2017
  article-title: Active surveillance for prostate cancer: how to do it right
  publication-title: Oncology
– volume: 190
  start-page: 2047
  issue: 6
  year: 2013
  end-page: 2053
  article-title: Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population
  publication-title: J Urol
– volume: 436
  start-page: 316
  year: 2014
  end-page: 318
  article-title: Serum crosslinked-N-terminal telopeptide of type I collagen (NTx) has prognostic implications for patients with initial prostate carcinoma (PCa): a pilot study
  publication-title: Clin Chim Acta
– volume: 192
  start-page: 1081
  issue: 4
  year: 2014
  end-page: 1087
  article-title: Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies
  publication-title: J Urol
– volume: 189
  start-page: 1110
  issue: 3
  year: 2013
  end-page: 1116
  article-title: Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study
  publication-title: J Urol
– volume: 113
  start-page: 382
  issue: 3
  year: 2015
  end-page: 389
  article-title: Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort
  publication-title: Br J Cancer
– volume: 106
  start-page: 1095
  issue: 6
  year: 2012
  end-page: 1099
  article-title: Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort
  publication-title: Br J Cancer
– volume: 68
  start-page: 123
  issue: 1
  year: 2015
  end-page: 131
  article-title: A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer
  publication-title: Eur Urol
– volume: 100
  start-page: 1603
  issue: 10
  year: 2009
  end-page: 1607
  article-title: Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer
  publication-title: Br J Cancer
– volume: 192
  start-page: 409
  issue: 2
  year: 2014
  end-page: 414
  article-title: Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy
  publication-title: J Urol
– volume: 14
  year: 2013
  article-title: Analytical validation of the Oncotype DX prostate cancer assay—a clinical RT-PCR assay optimized for prostate needle biopsies
  publication-title: BMC Genomics
– volume: 75
  start-page: 103
  issue: 1
  year: 2015
  end-page: 111
  article-title: Accuracy of the Prostate Health Index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy
  publication-title: Prostate
– volume: 34
  start-page: 2921
  issue: 5
  year: 2013
  end-page: 2927
  article-title: Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients
  publication-title: Tumour Biol
– volume: 43
  start-page: 1
  issue: 1
  year: 2016
  end-page: 6
  article-title: The Prostate Health Index: its utility in prostate cancer detection
  publication-title: Urol Clin North Am
– volume: 179
  start-page: 1587
  issue: 4
  year: 2008
  end-page: 1592
  article-title: PCA3: a molecular urine assay for predicting prostate biopsy outcome
  publication-title: J Urol
– volume: 167
  start-page: 1231
  issue: 3
  year: 2002
  end-page: 1234
  article-title: Expectant management of nonpalpable prostate cancer with curative intent: preliminary results
  publication-title: J Urol
– volume: 15
  year: 2015
  article-title: Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy
  publication-title: BMC Cancer
– volume: 193
  start-page: 1163
  issue: 4
  year: 2015
  end-page: 1169
  article-title: The Prostate Health Index selectively identifies clinically significant prostate cancer
  publication-title: J Urol
– volume: 35
  start-page: 135
  issue: 2
  year: 2017
  end-page: 149
  article-title: Prostate cancer diagnostics: clinical challenges and the ongoing need for disruptive and effective diagnostic tools
  publication-title: Biotechnol Adv
– volume: 317
  start-page: 909
  issue: 15
  year: 1987
  end-page: 916
  article-title: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
  publication-title: New England J Med
– volume: 59
  start-page: 96
  issue: 1
  year: 2011
  end-page: 105
  article-title: Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging
  publication-title: Eur Urol
– volume: 191
  start-page: 1743
  issue: 6
  year: 2014
  end-page: 1748
  article-title: Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy
  publication-title: J Urol
– volume: 60
  start-page: 826
  issue: 5
  year: 2002
  end-page: 830
  article-title: Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program
  publication-title: Urology
– volume: 7
  start-page: 129
  issue: 3
  year: 2014
  end-page: 134
  article-title: Reduced rate of repeated prostate biopsies observed in ConfirmMDx clinical utility field study
  publication-title: Am Health Drug Benefits
– volume: 16
  start-page: 487
  issue: 3
  year: 2014
  end-page: 492
  article-title: The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis
  publication-title: Asian J Androl
– volume: 5
  start-page: 463
  issue: 6
  year: 2010
  end-page: 466
  article-title: What are biomarkers?
  publication-title: Curr Opin HIV AIDS
– volume: 119
  start-page: 225
  issue: 2
  year: 2017
  end-page: 233
  article-title: Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients
  publication-title: BJU Int
– volume: 44
  issue: D1
  year: 2016
  article-title: Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation
  publication-title: Nucleic Acids Res
– volume: 190
  start-page: 419
  issue: 2
  year: 2013
  end-page: 426
  article-title: Early detection of prostate cancer: AUA guideline
  publication-title: J Urol
– volume: 15
  start-page: 7
  issue: 3
  year: 2017
  end-page: 10
  article-title: New US Preventive Service Task Force recommendations for prostate cancer screening: a needed update, but not enough
  publication-title: Einstein
– volume: 66
  start-page: 550
  issue: 3
  year: 2014
  end-page: 560
  article-title: A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling
  publication-title: Eur Urol
– volume: 30
  start-page: 1025
  issue: 6
  year: 2014
  end-page: 1031
  article-title: Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry
  publication-title: Curr Med Res Opin
– volume: 68
  start-page: 139
  issue: 1
  year: 2015
  end-page: 146
  article-title: Comparison between the four-kallikrein panel and Prostate Health Index for predicting prostate cancer
  publication-title: Eur Urol
– volume: 89
  start-page: 69
  year: 2016
  end-page: 75
  article-title: Patient-specific meta-analysis of 2 clinical validation studies to predict pathologic outcomes in prostate cancer using the 17-gene genomic prostate score
  publication-title: Urology
– volume: 33
  issue: 4
  year: 2015
  article-title: Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy
  publication-title: Urol Oncol
– volume: 69
  start-page: 532
  issue: 3
  year: 2007
  end-page: 535
  article-title: PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy
  publication-title: Urology
– volume: 429
  start-page: 46
  year: 2014
  end-page: 50
  article-title: PCA3 score of 20 could improve prostate cancer detection: results obtained on 734 Italian individuals
  publication-title: Clin Chim Acta
– volume: 70
  start-page: 740
  issue: 5
  year: 2016
  end-page: 748
  article-title: Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score
  publication-title: Eur Urol
– volume: 32
  start-page: 4066
  issue: 36
  year: 2014
  end-page: 4072
  article-title: Can urinary PCA3 supplement PSA in the early detection of prostate cancer?
  publication-title: J Clin Oncol
– volume: 62
  start-page: 2695
  issue: 9
  year: 2002
  end-page: 2698
  article-title: DD3(PCA3), a very sensitive and specific marker to detect prostate tumors
  publication-title: Cancer Res
– volume: 19
  issue: 87
  year: 2015
  article-title: The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation
  publication-title: Health Technol Asses
– volume: 4
  start-page: 130
  issue: 4
  year: 2016
  end-page: 135
  article-title: Prostate cancer biomarkers: are we hitting the mark?
  publication-title: Prostate Int
– volume: 9
  start-page: 3
  issue: 2
  year: 2016
  end-page: 10
  article-title: Novel biomarkers for the detection of prostate cancer
  publication-title: J Clin Urol
– volume: 152
  start-page: 1163
  issue: 4
  year: 1994
  end-page: 1167
  article-title: Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection
  publication-title: J Urol
– volume: 185
  start-page: 1650
  issue: 5
  year: 2011
  end-page: 1655
  article-title: A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range
  publication-title: J Urol
– volume: 2
  start-page: 882
  issue: 7
  year: 2016
  end-page: 889
  article-title: A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy
  publication-title: JAMA Oncol
– volume: 280
  start-page: 793
  issue: 3
  year: 2016
  end-page: 804
  article-title: Interobserver reproducibility of the PI-RADS version 2 lexicon: a multicenter study of six experienced prostate radiologists
  publication-title: Radiology
– volume: 72
  start-page: 250
  year: 2017
  end-page: 266
  article-title: What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel
  publication-title: Eur Urol
– volume: 196
  start-page: 690
  issue: 3
  year: 2016
  end-page: 696
  article-title: Prospective evaluation of the prostate imaging reporting and data system version 2 for prostate cancer detection
  publication-title: J Urol
– volume: 120
  start-page: 659
  year: 2017
  end-page: 665
  article-title: Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics—a decision analytical model
  publication-title: BJU Int
– volume: 8
  issue: 6
  year: 2013
  article-title: Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy
  publication-title: PLoS ONE
– volume: 106
  start-page: 1143
  issue: 8
  year: 2010
  end-page: 1147
  article-title: The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
  publication-title: BJU Int
– volume: 86
  start-page: 848
  issue: 5
  year: 2013
  end-page: 853
  article-title: Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 68
  start-page: 464
  issue: 3
  year: 2015
  end-page: 470
  article-title: A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer
  publication-title: Eur Urol
– volume: 170
  start-page: 2181
  issue: 6 Pt 1
  year: 2003
  end-page: 2185
  article-title: Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml
  publication-title: J Urol
– volume: 31
  start-page: 1428
  issue: 11
  year: 2013
  end-page: 1434
  article-title: Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort
  publication-title: J Clin Oncol
– volume: 19
  start-page: 277
  issue: 3
  year: 2016
  end-page: 282
  article-title: Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk
  publication-title: Prostate Cancer P D
– volume: 274
  start-page: 1214
  issue: 15
  year: 1995
  end-page: 1220
  article-title: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening
  publication-title: JAMA
– volume: 103
  start-page: 708
  issue: 5
  year: 2010
  end-page: 714
  article-title: A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands
  publication-title: Br J Cancer
– volume: 20
  start-page: 186
  issue: 2
  year: 2017
  end-page: 192
  article-title: Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer
  publication-title: Prostate Cancer Prostatic Dis
– volume: 464
  start-page: 293
  issue: 3
  year: 2014
  end-page: 300
  article-title: Prognostic prostate tissue biomarkers of potential clinical use
  publication-title: Virchows Arch
– volume: 317
  start-page: 909
  issue: 15
  year: 1987
  ident: bibr15-1010428318799255
  publication-title: New England J Med
  doi: 10.1056/NEJM198710083171501
– volume: 30
  start-page: 4223
  issue: 34
  year: 2012
  ident: bibr14-1010428318799255
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.42.6858
– volume: 152
  start-page: 1163
  issue: 4
  year: 1994
  ident: bibr17-1010428318799255
  publication-title: J Urol
  doi: 10.1016/S0022-5347(17)32528-4
– volume: 190
  start-page: 389
  issue: 2
  year: 2013
  ident: bibr48-1010428318799255
  publication-title: J Urol
  doi: 10.1016/j.juro.2013.02.005
– volume: 35
  start-page: 135
  issue: 2
  year: 2017
  ident: bibr3-1010428318799255
  publication-title: Biotechnol Adv
  doi: 10.1016/j.biotechadv.2016.11.009
– volume: 280
  start-page: 793
  issue: 3
  year: 2016
  ident: bibr44-1010428318799255
  publication-title: Radiology
  doi: 10.1148/radiol.2016152542
– volume: 33
  start-page: 944
  issue: 8
  year: 2015
  ident: bibr77-1010428318799255
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.59.0026
– volume: 24
  start-page: 352
  issue: 5
  year: 2017
  ident: bibr2-1010428318799255
  publication-title: Int J Urol
  doi: 10.1111/iju.13326
– volume: 106
  start-page: 1143
  issue: 8
  year: 2010
  ident: bibr25-1010428318799255
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2010.09286.x
– start-page: 2100
  volume-title: Sabiston textbook of surgery: the biological basis of modern surgical practice
  year: 2017
  ident: bibr1-1010428318799255
– volume: 167
  start-page: 1231
  issue: 3
  year: 2002
  ident: bibr16-1010428318799255
  publication-title: J Urol
  doi: 10.1016/S0022-5347(05)65271-8
– volume: 20
  start-page: 186
  issue: 2
  year: 2017
  ident: bibr75-1010428318799255
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/pcan.2016.58
– volume: 19
  start-page: 277
  issue: 3
  year: 2016
  ident: bibr78-1010428318799255
  publication-title: Prostate Cancer P D
  doi: 10.1038/pcan.2016.15
– volume: 68
  start-page: 123
  issue: 1
  year: 2015
  ident: bibr71-1010428318799255
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2014.11.030
– volume: 60
  start-page: 826
  issue: 5
  year: 2002
  ident: bibr6-1010428318799255
  publication-title: Urology
  doi: 10.1016/S0090-4295(02)01958-1
– volume: 90
  start-page: 148
  year: 2016
  ident: bibr41-1010428318799255
  publication-title: Urology
  doi: 10.1016/j.urology.2016.01.012
– volume: 14
  year: 2013
  ident: bibr32-1010428318799255
  publication-title: BMC Genomics
  doi: 10.1186/1471-2164-14-690
– volume: 190
  start-page: 419
  issue: 2
  year: 2013
  ident: bibr47-1010428318799255
  publication-title: J Urol
  doi: 10.1016/j.juro.2013.04.119
– volume: 86
  start-page: 848
  issue: 5
  year: 2013
  ident: bibr73-1010428318799255
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2013.04.043
– volume: 34
  start-page: 2921
  issue: 5
  year: 2013
  ident: bibr11-1010428318799255
  publication-title: Tumour Biol
  doi: 10.1007/s13277-013-0854-4
– volume: 31
  start-page: 1428
  issue: 11
  year: 2013
  ident: bibr34-1010428318799255
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.46.4396
– volume: 170
  start-page: 2181
  issue: 6
  year: 2003
  ident: bibr20-1010428318799255
  publication-title: J Urol
  doi: 10.1097/01.ju.0000095460.12999.43
– volume: 62
  start-page: 2695
  issue: 9
  year: 2002
  ident: bibr22-1010428318799255
  publication-title: Cancer Res
– volume: 75
  start-page: 103
  issue: 1
  year: 2015
  ident: bibr60-1010428318799255
  publication-title: Prostate
  doi: 10.1002/pros.22898
– volume: 185
  start-page: 1650
  issue: 5
  year: 2011
  ident: bibr19-1010428318799255
  publication-title: J Urol
  doi: 10.1016/j.juro.2010.12.032
– volume: 33
  issue: 4
  year: 2015
  ident: bibr61-1010428318799255
  publication-title: Urol Oncol
  doi: 10.1016/j.urolonc.2014.12.002
– volume: 15
  start-page: 7
  issue: 3
  year: 2017
  ident: bibr4-1010428318799255
  publication-title: Einstein
  doi: 10.1590/s1679-45082017ed4151
– volume: 103
  start-page: 708
  issue: 5
  year: 2010
  ident: bibr68-1010428318799255
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6605815
– volume: 83
  start-page: 1362
  issue: 6
  year: 2014
  ident: bibr51-1010428318799255
  publication-title: Urology
  doi: 10.1016/j.urology.2014.02.035
– volume: 7
  start-page: 129
  issue: 3
  year: 2014
  ident: bibr70-1010428318799255
  publication-title: Am Health Drug Benefits
– volume: 274
  start-page: 1214
  issue: 15
  year: 1995
  ident: bibr18-1010428318799255
  publication-title: JAMA
  doi: 10.1001/jama.1995.03530150038031
– volume: 15
  year: 2015
  ident: bibr54-1010428318799255
  publication-title: BMC Cancer
  doi: 10.1186/s12885-015-1623-0
– volume: 436
  start-page: 316
  year: 2014
  ident: bibr10-1010428318799255
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2014.06.025
– volume: 192
  start-page: 409
  issue: 2
  year: 2014
  ident: bibr38-1010428318799255
  publication-title: J Urol
  doi: 10.1016/j.juro.2014.02.003
– volume: 120
  start-page: 659
  year: 2017
  ident: bibr28-1010428318799255
  publication-title: BJU Int
  doi: 10.1111/bju.13861
– volume: 89
  start-page: 69
  year: 2016
  ident: bibr72-1010428318799255
  publication-title: Urology
  doi: 10.1016/j.urology.2015.12.008
– volume: 189
  start-page: 1110
  issue: 3
  year: 2013
  ident: bibr31-1010428318799255
  publication-title: J Urol
  doi: 10.1016/j.juro.2012.08.219
– volume: 76
  start-page: 1019
  issue: 11
  year: 2016
  ident: bibr56-1010428318799255
  publication-title: Prostate
  doi: 10.1002/pros.23197
– volume: 31
  issue: 5
  year: 2017
  ident: bibr5-1010428318799255
  publication-title: Oncology
– volume: 75
  start-page: 1951
  issue: 16
  year: 2015
  ident: bibr55-1010428318799255
  publication-title: Prostate
  doi: 10.1002/pros.23096
– volume: 32
  start-page: 4066
  issue: 36
  year: 2014
  ident: bibr52-1010428318799255
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.52.8505
– volume: 68
  start-page: 139
  issue: 1
  year: 2015
  ident: bibr64-1010428318799255
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2014.08.010
– volume: 6
  year: 2008
  ident: bibr63-1010428318799255
  publication-title: BMC Med
  doi: 10.1186/1741-7015-6-19
– volume: 68
  start-page: 464
  issue: 3
  year: 2015
  ident: bibr21-1010428318799255
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2014.10.021
– volume: 193
  start-page: 1163
  issue: 4
  year: 2015
  ident: bibr58-1010428318799255
  publication-title: J Urol
  doi: 10.1016/j.juro.2014.10.121
– volume: 12
  start-page: 245
  issue: 3
  year: 2011
  ident: bibr37-1010428318799255
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70295-3
– volume: 66
  start-page: 550
  issue: 3
  year: 2014
  ident: bibr33-1010428318799255
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2014.05.004
– volume: 100
  start-page: 1603
  issue: 10
  year: 2009
  ident: bibr29-1010428318799255
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6605058
– volume: 19
  issue: 87
  year: 2015
  ident: bibr65-1010428318799255
  publication-title: Health Technol Asses
  doi: 10.3310/hta19870
– volume: 464
  start-page: 293
  issue: 3
  year: 2014
  ident: bibr7-1010428318799255
  publication-title: Virchows Arch
  doi: 10.1007/s00428-014-1540-7
– volume: 21
  start-page: 3061
  issue: 13
  year: 2015
  ident: bibr57-1010428318799255
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-3334
– volume: 179
  start-page: 1587
  issue: 4
  year: 2008
  ident: bibr49-1010428318799255
  publication-title: J Urol
  doi: 10.1016/j.juro.2007.11.038
– volume: 191
  start-page: 1743
  issue: 6
  year: 2014
  ident: bibr50-1010428318799255
  publication-title: J Urol
  doi: 10.1016/j.juro.2013.12.005
– volume: 30
  start-page: 1025
  issue: 6
  year: 2014
  ident: bibr74-1010428318799255
  publication-title: Curr Med Res Opin
  doi: 10.1185/03007995.2014.899208
– volume: 106
  start-page: 1095
  issue: 6
  year: 2012
  ident: bibr35-1010428318799255
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2012.39
– volume: 71
  start-page: 618
  issue: 4
  year: 2017
  ident: bibr62-1010428318799255
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2016.08.003
– volume: 9
  start-page: 3
  issue: 2
  year: 2016
  ident: bibr8-1010428318799255
  publication-title: J Clin Urol
  doi: 10.1177/2051415816656121
– volume: 67
  start-page: 326
  issue: 2
  year: 2015
  ident: bibr40-1010428318799255
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2014.05.039
– volume: 40
  start-page: 244
  issue: 2
  year: 2016
  ident: bibr9-1010428318799255
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000000530
– volume: 192
  start-page: 1081
  issue: 4
  year: 2014
  ident: bibr69-1010428318799255
  publication-title: J Urol
  doi: 10.1016/j.juro.2014.04.013
– volume: 16
  start-page: 487
  issue: 3
  year: 2014
  ident: bibr66-1010428318799255
  publication-title: Asian J Androl
  doi: 10.4103/1008-682X.125390
– volume: 429
  start-page: 46
  year: 2014
  ident: bibr67-1010428318799255
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2013.10.022
– volume: 5
  start-page: 463
  issue: 6
  year: 2010
  ident: bibr12-1010428318799255
  publication-title: Curr Opin HIV AIDS
  doi: 10.1097/COH.0b013e32833ed177
– volume: 2
  start-page: 882
  issue: 7
  year: 2016
  ident: bibr30-1010428318799255
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2016.0097
– volume: 4
  start-page: 130
  issue: 4
  year: 2016
  ident: bibr13-1010428318799255
  publication-title: Prostate Int
  doi: 10.1016/j.prnil.2016.07.002
– volume: 69
  start-page: 532
  issue: 3
  year: 2007
  ident: bibr24-1010428318799255
  publication-title: Urology
  doi: 10.1016/j.urology.2006.12.014
– volume: 14
  start-page: 19
  issue: 1
  year: 2016
  ident: bibr46-1010428318799255
  publication-title: J Natl Compr Canc Netw
  doi: 10.6004/jnccn.2016.0004
– volume: 72
  start-page: 250
  year: 2017
  ident: bibr42-1010428318799255
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2017.02.026
– volume: 113
  start-page: 382
  issue: 3
  year: 2015
  ident: bibr36-1010428318799255
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2015.223
– volume: 44
  issue: 1
  year: 2016
  ident: bibr26-1010428318799255
  publication-title: Nucleic Acids Res
– volume: 8
  issue: 6
  year: 2013
  ident: bibr39-1010428318799255
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0066855
– volume: 119
  start-page: 225
  issue: 2
  year: 2017
  ident: bibr45-1010428318799255
  publication-title: BJU Int
  doi: 10.1111/bju.13465
– volume: 190
  start-page: 2047
  issue: 6
  year: 2013
  ident: bibr76-1010428318799255
  publication-title: J Urol
  doi: 10.1016/j.juro.2013.06.017
– volume: 59
  start-page: 96
  issue: 1
  year: 2011
  ident: bibr23-1010428318799255
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2010.10.024
– volume: 43
  start-page: 1
  issue: 1
  year: 2016
  ident: bibr59-1010428318799255
  publication-title: Urol Clin North Am
  doi: 10.1016/j.ucl.2015.08.001
– volume: 196
  start-page: 690
  issue: 3
  year: 2016
  ident: bibr43-1010428318799255
  publication-title: J Urol
  doi: 10.1016/j.juro.2016.04.057
– volume: 70
  start-page: 740
  issue: 5
  year: 2016
  ident: bibr27-1010428318799255
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2016.04.012
– volume: 63
  start-page: 201
  issue: 2
  year: 2013
  ident: bibr53-1010428318799255
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2012.07.030
SSID ssj0015996
Score 2.272402
SecondaryResourceType review_article
Snippet Prostate cancer presents itself in a heterogeneous way with both aggressive and indolent forms. Despite the controversy surrounding its use, prostate-specific...
Prostate cancer presents itself in a heterogeneous way with both aggressive and indolent forms. Despite the controversy surrounding its use, prostate-specific...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 101042831879925
SubjectTerms Biomarkers, Tumor - metabolism
Humans
Male
Prognosis
Prostate - metabolism
Prostate-Specific Antigen - metabolism
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - metabolism
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwEB4hDqUXRHmU0IeMVFXiELGxnXh9qigqAiR6KhK3yI-xuhIKaJe98OuZyWPZbWl76TWJY3vGnvksz3wD8CkkVxRp7HJDvjvXpZU5oRCVO-1LO1KBCUQ42uJ7dX6tL2_Km6VSXxwT1tEDd4I7DsZEpxL9BK0unfEhlVJH4yRWRqY2zXdkR8Nhqr8_YNKR50tJMg0Fnw0Ul9a2ktP6lpxQy9X_EsD8PU5yKdir9T9nW7DZA0dx0g34Daxhsw0bp0O9tm14ddVfk-_AxckUReulJo8YxT1ndhCmFIFVPBWccs9ROdOZmM8wzW_FpBEEBMWQJimG3Kkvu3B99u3H6Xne10zIA9Ou5CrYiKb0TlYpOJS-sBoLT_IiaCWDlkkmF73TGJVDRKfHVgebgi-D1TGqPVhv7hrcB6GjiiRvS3s0kBKjk2P0FVsAW5AVSBkcD0KsQ08oznUtbuui5xD_VewZHC1a3HdkGn_59ivrZfEd02C3D2hx1P3iqP-1ODI4HLRakzb4LsQ1eDef1XzS5fQlaTJ422l50ZXihGGCbhmYFf2vjGX1TTP52VJzVxW1rajfz7xS6t4ezP44y4P_Mct38Jpg3LiLfHsP6w_TOX4gqPTgP7a74gmYpw1q
  priority: 102
  providerName: Directory of Open Access Journals
Title Are localized prostate cancer biomarkers useful in the clinical practice?
URI https://journals.sagepub.com/doi/full/10.1177/1010428318799255
https://www.ncbi.nlm.nih.gov/pubmed/30204063
https://www.proquest.com/docview/2102321027
https://pubmed.ncbi.nlm.nih.gov/PMC6602068
https://doaj.org/article/c77da3f592e945a7bcf524d7a2e672f8
Volume 40
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6VrQRcKiiv0FIZCSFxCCW2E8enaqlYFSQ4oFb0FvlZVqLZKrs5wK9nJo8tSwFxipQ4suOZsb94Zr4BeOGiybJYmlTh3p3KXPMUUYhIjbS5fiMcEYhQtMWn4uRMfjjPz7egHnNhhhlcvqawKhxRt1iTddNp9OHgZMRrRlhfUKlsjaD4qF1dVv1p91hUg-6Qe7q9JM-2o3jI7-mY3XYLtrnCcU1gezr7_OV07XcgspLOP4qrE3Vw7di80efGRtbx_f8JpN6MtfwlYKzbw2b3YGcAn2zaa8t92Ar1Ltw5Hmu-7cLtj4Or_QG8nzaBdTvd_Efw7IqyQxCXMkdq0jBK26fInmbJ2mXAaWPzmiGYZGOqJRvzr44ewtns3enxSTrUXUgdUbekwmkfVG4NL6IzgdtMy5BZrwzCM-4kjzwab40MXpgQgpGllk5HZ3OnpffiEUzqRR2eAJNeeKOsRjt3qAje8DLYglYRneFKEhM4HCexcgMpOdXG-FZlAw_579OewKv1G1c9Icc_2r4luazbEZV2d2PRXFSDZVZOKW9ERG0IWuY4WBdzLvFjeSgUj2UCz0epVigN8qeYOizaZUV_y5QCxVUCj3spr7sSlHSM8C8BtSH_jbFsPqnnXzt676LAdwvs9yVpSjVaxF-_8un_NtyDuwj3yj5Cbh8mq6YNzxBSrezBYAcH3ZHETzbFGk4
linkProvider SAGE Publications
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB7BVqK9ICiv8DQSQuIQ2thOHJ_QUrHaQtsD2oreIj9hpSpbZbuX_npmsknoUkBcEzt-jGf8RTPzDcAbF02WxdKkCu_uVOaap4hCRGqkzfW-cEQgQtEWJ8X0VH4-y8-ulfrqdnD5nsKqcEatsR60u80TzwjmC6qSrREP34Ytme8X5Qi2xpOv32aDC4F4R1pXJxoa6vDLR3njGxt3Ukvd_ye8eTNs8lrsV3sdTe7B3Q5HsvFa8PfhVqh3YfugL9-2C3eOO6_5AzgcN4G1l9b8Knh2QYkeCDGZI4k3jDLwKUinWbLVMsTVOZvXDHEh67MmWZ9K9eEhnE4-zQ6maVdCIXXEwpIKp31QuTW8iM4EbjMtQ2a9Moi0uJM88mi8NTJ4YUIIRpZaOh2dzZ2W3otHMKoXdXgCTHrhjbIaVdahTL3hZbAFGQSdoVGICez1m1i5jl-cylycV1lHKf77tifwbuhxsebW-EfbjySXoR2xYrcPFs33qlOyyinljYh44IKWOU7WxZxLXCwPheKxTOB1L9UKpUGuEVOHxWpZ0Y8vZTNxlcDjtZSHoQTlDyOSS0BtyH9jLptv6vmPlqm7KLBvgeO-pZNS9Yf7r6t8-r8NX8H2dHZ8VB0dnnx5BjuI4sp14NtzGF02q_ACkdKlfdnpxE_pbgbA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB7BVipcEBQo4WkkhMQhtLGdOD6hpbBqeVQItaK3yE9Yqcqust0Lv56ZrLOwFBCnSIkdP8Zjf9bMfAPwzEVTFLE2ucKzO5el5jmiEJEbaUu9LxwRiJC3xXF1eCrfnZVnyTeHYmHSDC5eklsV9qjfrEm75z7uJRsjPguC-oIyZWvExFdhC2819f4ItsaTz19O1mYE4h7pzZ242VCFn3bKS__YOJd6-v4_Yc7LrpO_-H_1R9LkJtxIWJKNV8K_BVdCuwPXDoYUbjuw_TFZzm_D0bgLrD-4pt-DZ3MK9kCYyRxJvWMUhU-OOt2CLRchLs_ZtGWIDdkQOcmGcKpXd-B08vbk4DBPaRRyR0wsuXDaB1Vaw6voTOC20DIU1iuDaIs7ySOPxlsjgxcmhGBkraXT0dnSaem9uAujdtaGe8CkF94oq1FtHcrVG14HW9GmoAvcGGIGe8MkNi5xjFOqi_OmSLTiv097Bi_WNeYrfo1_lH1NclmXI2bs_sWs-9okRWucUt6IiIsuaFliZ10sucTB8lApHusMng5SbVAaZB4xbZgtFw1dfimiiasMdldSXjclKIYY0VwGakP-G33Z_NJOv_Vs3VWFdSts9zmtlGZY4H8d5f3_LfgEtj-9mTQfjo7fP4DrCOTqle_bQxhddMvwCMHShX2cVOIH20YH0A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Are+localized+prostate+cancer+biomarkers+useful+in+the+clinical+practice%3F&rft.jtitle=Tumor+biology&rft.au=Carneiro%2C+Arie&rft.au=Kayano%2C+Paulo+Priante&rft.au=Gomes+Barbosa%2C+%C3%81lan+Roger&rft.au=Wroclawski%2C+Marcelo+Langer&rft.date=2018-09-01&rft.issn=1010-4283&rft.eissn=1423-0380&rft.volume=40&rft.issue=9&rft.spage=1010428318799255&rft.epage=1010428318799255&rft_id=info:doi/10.1177%2F1010428318799255&rft_id=info%3Apmid%2F30204063&rft.externalDocID=PMC6602068
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1010-4283&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1010-4283&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1010-4283&client=summon